Recognition of the cytoprotective functions of autophagy that occur in tumor cells exposed to various forms of chemotherapy or radiation has generated intense interest in the possibility that pharmacological interference with autophagy could provide a clinical strategy for overcoming therapeutic resistance. Multiple clinical trials are currently in progress to evaluate the antimalarial agent chloroquine (generally in its clinical formulation as hydroxychloroquine) and its impact on various forms of cancer therapy. In this commentary/review, we focus on the relatively limited number of studies in the literature where chloroquine has been tested in combination with chemotherapy or radiation in experimental tumor-bearing animal models. We also present recent data from our own laboratories, in cell culture experiments as well as in vivo studies, which demonstrate that neither chloroquine nor silencing of an autophagy regulatory gene was effective in conferring radiation sensitivity in an experimental model of breast cancer.
Introduction
In recent years, it has been recognized that one potential mechanism of resistance to chemotherapy as well as radiotherapy in cancer could be the promotion of protective autophagy; this recognition has generated interest in the possibility that interference with autophagy could enhance sensitivity to treatment (Abedin et al., 2007; Amaravadi et al., 2007; Apel et al., 2008; Boya et al., 2005; Bristol et al., 2012; Djavaheri-Mergny et al., 2007; Kanzawa et al., 2004; Kondo et al., 2005; Paglin et al., 2001; Qadir et al., 2008; Sotelo et al., 2006; Wilson et al., 2011 ). An extensive number of studies in cell culture (for example, Amaravadi et al., 2007; Apel et al., 2008; Boya et al., 2005; Bristol et al., 2012; Kanzawa et al., 2004; Livesey et al., 2009; Ma et al., 2011; Paglin et al., 2001; Qadir et al., 2008; Solomon and Lee, 2009; Wilson et al., 2011; Zhao et al., 2005) , as well as a more limited number of studies in animal models (Carew et al., 2010; Ding et al., 2011; Fu et al., 2009; Ghadami et al., 2012; Godbole et al., 2012; Guo et al., 2012; Hu et al., 2012; Jiang et al., 2010; Liang et al., 2012; Loehberg et al., 2012; Lopez et al., 2011; Mirzoeva et al., 2011; Pan et al., 2011; Rao et al., 2012; Shi et al., 2011; Sasaki et al., 2012; Wu et al., 2010; Xu et al., 2011) have been performed combining chloroquine or hydroxychloroquine with chemotherapeutic drugs or radiation. Furthermore, a number of clinical trials have been initiated to test this premise in patients (Sotelo et al., 2006 ; U.S. National
Institutes of Health, 2012) .
In view of the fact that therapeutic efficacy of both antitumor drugs and radiation may be highly dependent on the immune system (Michaud et al., 2011; Golden et al., 2012; Martins et al., 2012) , and since, with few exceptions, studies in the current literature have been performed using tumor xenografts, we assessed the influence of treatment with chloroquine on sensitivity to J P E T # 1 9 9 8 0 2 P I P 5 radiation in the 4T1 syngeneic murine breast tumor model. Complementary experiments were performed in cell culture evaluating the impact of chloroquine as well as genetic silencing of the autophagy regulatory gene, Atg12, on sensitivity to radiation in murine 4T1 breast tumor cells.
Given that our studies, both in cell culture as well as in vivo, appeared to indicate that either pharmacologic or genetic interference with autophagy fails to confer radiation sensitization, it appeared to be relevant to review the literature relating to animal model systems combining chloroquine with chemotherapy and radiotherapy in order to evaluate the preclinical evidence that might support the ongoing clinical trials.
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Materials and Methods
Cell Culture and Treatment 4T1 cells were obtained from ATCC. 4T1 derived cell lines were grown from frozen stocks in basal RPMI 1640 supplemented with 5% FBS, 5% BCS, 2 mmol/L l-glutamine, and penicillin/streptomycin (0.5 mL/100 mL medium). All cells were maintained at 37°C under a humidified, 5% CO2 atmosphere. Cells were routinely subcultured by trypsinization (0.25% trypsin, 0.03% EDTA, Gibco) upon reaching confluence. All cell cultures were examined by microscope for bacterial and fungal contamination prior to experiments.
Additionally, all cell lines were determined to be free of mycoplasma.
For in vitro radiation experiments, 4T1 cells were treated for 1 h with chloroquine before radiation in an X-ray irradiator (RS2000) at the indicated doses. After treatment, medium was changed and protein was collected 4 h after treatment for Western Blotting. For clonogenic assays, cells were plated in 12 well plates at a density of 300 cells per well, treated as described above and allowed to recover for 7 days after treatment. Cells were then fixed and stained with crystal violet (BD), the stain was solubilized with 30% acetic acid and absorbance was measured at 540 nm. 4T1 Atg12 shRNA inducible cells were generated as described previously (Maycotte et al., 2012) . Briefly, 4T1 cells were transduced with lentiviruses containing a pTRIPZ nonsilencing shRNA or an Atg12 mouse shRNA cloned from a pGIPZ shRNAmir (V2LMM_72549) plasmid (Open Biosystems). Cells were grown in DMEM with 10% tetracycline-free FBS (Hyclone), selected with puromycin and clones were isolated and validated for ATG12
knockdown. For shRNA induction, cells were treated with 1 µg/ml doxycycline (Clontech) for 72 h, replacing doxycycline every 24 h. For radiation treatment, cells were plated in 12 well plates at a density of 200 cells per well, treated ± doxycycline for 72 h, and irradiated at the
indicated doses. After a 7 day recovery period, cells were fixed and clonogenic growth was evaluated as described above.
Western Blotting Cells were washed with PBS and lysed with RIPA buffer. Protein was quantitated using Bradford reagent (Bio-Rad). 20 μ g of protein were loaded in a 10% SDS-PAGE and PVDF membranes (Millipore) were probed with anti-ATG12 (Cell Signaling, D88H11) or actin antibodies (Sigma, A5441). For LC3 Western Blots, 7.5 μg of protein were used and probed with anti-LC3 antibody (Novus Biologicals, NB100-2220).
Animal Studies Female BALB/c mice, 8 weeks old, were purchased from Jackson Laboratories and were maintained in groups of four per cage with access to food and water. The animals were acclimated at least two days before use and maintained throughout at standard conditions: PBS. The CQ doses chosen were based on the available literature, where studies have generally been performed using CQ at 50-60mg/kg (Carew et al., 2010; Ding et al., 2011; Fu et al., 2009 ; , 2012; Godbole et al., 2012; Guo et al., 2012; Hu et al., 2012; Jiang et al., 2010; Liang et al., 2012; Loehberg et al., 2012; Lopez et al., 2011; Mirzoeva et al., 2011; Pan et al., 2011; Rao et al., 2012; Shi et al., 2011; Sasaki et al., 2012; Wu et al., 2010; Xu et al., 2011) .
Additional experiments were conducted where the mice were exposed to γ -irradiation using a 137 Cs irradiator as indicated: (e) 5 Gy IR, (f) 10 Gy IR, (g) 15 Gy IR, (h) 10Gy IR + 14 days CQ ip. Each group consisted of 6-8 mice. Irradiation was performed on day 3 and chloroquine (50mg/kg) or saline treatment was initiated on day 3 and was repeated every day for 14 days.
Tumor growth was monitored multiple times per week by bioluminescence. Upon sacrifice, tumors were resected and weighed.
Statistical Analysis All of the data are represented as means ± SE. Statistical differences were determined using StatView statistical software. Comparisons were made using a one-way J P E T # 1 9 9 8 0 2 P I P
Results
Studies in 4T1 cells in culture Extensive evidence in the literature supports a role for autophagy as a cytoprotective tumor survival pathway that is induced by exposure to chemotherapy or radiation (Abedin et al., 2007; Amaravadi et al., 2007; Apel et al., 2008; Boya et al., 2005; Bristol et al., 2012; Djavaheri-Mergny et al., 2007; Kanzawa et al., 2004; Kondo et al., 2005; Paglin et al., 2001; Qadir et al., 2008; Sotelo et al., 2006; Wilson et al., 2011) . In this work we treated 4T1 cells with radiation and different doses of chloroquine to block autophagy. Figure 1A shows induction of autophagy in 4T1 cells after radiation treatment (2, 5 and 10 Gy with and without exposure to chloroquine (10, 25 and 30µM) when evaluated by Western blotting for LC3. During autophagy, LC3, the mammalian homolog of Atg8, is cleaved and conjugated to phosphatidylethanolamine. This modified form, termed LC3II, is involved in the elongation of the autophagosome (Mizushima et al., 2010) . However, LC3II is also degraded in the lysosome after autophagosome-lysosome fusion (Mizushima et al., 2010; Klionsky et al., 2012) . Therefore, in order to measure autophagic flux, lysosomal inhibitors such as chloroquine are used to inhibit LC3II degradation, since in the absence of these inhibitors, an autophagy-inducing treatment can result in a modest increase or even a decrease in the amount of LC3II. The relevant parameter in this assay is the difference in the amount of LC3II in the presence and absence of lysosomal inhibitors (Klionsky et al., 2012) . In Figure 1A , chloroquine by itself increased LC3II due to inhibition of basal autophagy, and LC3II was increased when compared to untreated controls at Genetic inhibition of autophagy via silencing of ATG12 was performed to confirm the results of the experiments utilizing pharmacological inhibition. In a previous report, we developed 4T1 cells with an inducible Atg12 shRNA and complementary controls with non-silencing shRNA (Maycotte et al., 2012) . Figure 2 presents the results of studies assessing radiation sensitivity in these 4T1 cells by a clonogenic survival assay. Doxycycline treatment decreased ATG12 protein levels ( Figure 2A ), with the consequent suppression of radiation-induced autophagy in 4T1 cells at all radiation doses used in this study ( Figure 2B ). However, these experiments clearly demonstrate lack of sensitization by Atg12 silencing as the sensitivity to doses of 2, 5 and 10 Gy is essentially identical in the silenced and non-silenced cells with and without doxycycline ( Figure 2C ).
Studies of 4T1 cells in an animal model
A quite extensive body of evidence has been generated in support of the presumption that chloroquine has the potential to sensitize tumor cells to radiation or chemotherapy, ostensibly via the inhibition of autophagy (Amaravadi et al., 2007; Apel et al., 2008; Boya et al., 2005; Bristol et al., 2012; Kanzawa et al., 2004; Livesey et al., 2009; Ma et al., 2011; Paglin et al., 2001; Qadir et al., 2008; Solomon and Lee, 2009; Wilson et al., 2011; Zhao et al., 2005) . In conjunction with the genetic and pharmacological studies that were performed in cell culture to inhibit autophagy induced by radiation, experiments were designed to assess the impact of chloroquine on the response to radiation using the murine 50 and 100 mg/kg) were monitored for effects on tumor volume by bioluminescence and final tumor weight. A radiation-dose-dependent decrease in tumor size was detected by bioluminescence measurement ( Figure 3A ), which was supported by assessment of tumor weight at the termination of the study ( Figure 3B ). Chloroquine alone had no impact on tumor weight (3D); although the bioluminescence assay seemed to suggest acceleration of tumor growth, this was not significant for any dose of the drug (3C). When 50mg/kg chloroquine (the dose generally used in vivo) was combined with 10Gy radiation, both the bioluminescence (3E), and final tumor weight determination (3F) indicated that the impact of the combination treatment was no greater than for radiation alone. Of note, with all treatments, animal weights remained consistent throughout the study (not shown).
Discussion
Studies in the literature relating to sensitization by chloroquine Multiple studies have been published indicating that genetic or pharmacological interference with autophagy can enhance the response to radiation (for example, Apel et al., 2008; Bristol et al., 2012; Chaachouay et al., 2011; Gaudin and Yielding, 1969; Jiang et al., 2010; Lim et al., 2012; Livesey et al., 2009; Pazmino and Yuhas, 1974; Solomon and Lee, 2009; Wilson et al., 2011; Zhao et al., 2005) by the silencing of autophagy-regulatory genes, with the consequent enhancement of radiation sensitivity (Bristol et al., 2012; Wilson et al., 2011) .
These findings raise the compelling question as to whether the efforts to utilize autophagy inhibition as a clinical strategy for chemosensitization and radiosensitization might be somewhat premature in the absence of sufficient and rigorous supporting preclinical data. In reviewing the available literature, there are clearly studies where the potential impact of chloroquine was realized in terms of the impact on tumor growth; however, in a number of studies, only very modest effects are evident in animal models assessing chemosensitization by chloroquine.
Furthermore, few studies have demonstrated prolongation of survival in tumor bearing animals.
A review of the relevant literature is presented below.
In recent studies by Ghadimi et al (Ghadimi et al., 2012) , chloroquine clearly enhanced sensitivity to a dual PI3K/mTOR inhibitor in a xenograft model of malignant peripheral nerve sheath tumors. In contrast, Mirzoeva et al demonstrated minimal sensitization to an agent with a similar mechanism of action in a xenograft model of pancreatic cancer (Mirzoeva et al., 2011) .
These differences could be related to the tumor models utilized, as Lopez et al (Lopez et al., 2011) reported quite pronounced sensitization to an HDAC inhibitor in studies that were also performed using malignant peripheral nerve sheath tumors; in the latter report, the combination with chloroquine also reduced lung tumor metastases.
With regard to the combination of chloroquine with some of the more conventional antitumor effects were evident in models of hepatocellular carcinoma utilizing oxaliplatin , Sorafenib or cisplatin, although the combination with 5-FU did appear to be quite effective (Guo et al., 2012) . Again, one might ascribe these diverse findings to the generally high degree of resistance to therapy in hepatocellular carcinoma that may not be susceptible to sensitization solely through the suppression of autophagy; that is, drug resistance could arise, in part, from drug degradation by hepatic enzymes.
With regards to a number of other agents of varying mechanisms of action, enhanced effectiveness of a Src family kinase inhibitor was observed when combined with chloroquine in a xenograft model of prostate cancer (Wu et al., 2010) , to IL-2 in a model of murine colorectal carcinoma (Liang et al., 2012) , and to Bevacizumab in glioblastoma ; the latter two findings are of particular interest and relevance and will be addressed in more detail below.
Conversely, only quite modest improvement of the response to chemotherapeutic agents was detected for chloroquine in combination with an mTOR inhibitor in MCF-7 xenografts (Loehberg et al., 2012) , with voranistat in colon carcinoma (Carew et al., 2010) , with perifosine in lung cancer xenografts (Fu et al., 2009) , with a dual PI3K/Akt/mTOR inhibitor in NSCLC xenografts (Xu et al., 2011) , with a retinoic acid metabolism blocker in breast tumor cells (Godbole et al., 2012) , and with panobinostat in breast cancer (Rao et al., 2012) ; in the latter studies, the lack of impact could be ascribed to the use of an unusually low dose of chloroquine of 10 mg/kg, which was apparently necessitated by the high degree of toxicity that was observed with chloroquine alone in this work.
A particularly relevant issue is that it is frequently unclear as to whether chloroquine has achieved levels in the tumor cells that are likely to be therapeutically effective in terms of the The studies by Liang et al are noteworthy in being virtually the only ones that demonstrated a clear increase in long-term survival for the combination treatment with chloroquine (Liang et al., 2012) . It is possible that this may be related to the experiments having been performed in a syngeneic, immune competent system. However, the use of immune-competent animals was necessitated by the fact that these studies involved a component of the immune system; therefore at this juncture it cannot be convincingly argued that immune-competent animals would necessarily prove to be more predictive of the impact of autophagy inhibition on chemotherapeutic sensitivity than xenograft models. In fact, the studies by Hu et al. (2012) ,
where genetic inhibition of autophagy demonstrated marked effects on tumor growth delay as well as survival of the tumor bearing animals, were performed in xenograft models.
With respect to the studies of Hu combining chloroquine with Bevacizumab in glioblastoma, while an increase in survival of the tumor-bearing animals is evident, it is critical to note that this occurred only under the conditions where the implanted tumor cells had been genetically engineered for silencing of ATG7; surprisingly, no survival studies were presented for the combination treatment with chloroquine, raising the possibility that chloroquine might have failed to achieve the desired outcome in this experimental system. As with virtually all of the data reported in the literature, the outcome of the combination treatment with chloroquine was essentially one of tumor growth delay without any substantive decline in tumor size over .
In comparing the pharmacological experiments with the genetic silencing studies in the animal models, it can be argued that the studies by Hu do in fact appear to provide proof of principle for autophagy inhibition as a potentially effective therapeutic strategy.
However, it can also be concluded that chloroquine is unlikely to be uniformly effective in suppressing autophagy in tumors in vivo. Interestingly, although there is fairly extensive literature on the pharmacokinetics of chloroquine in humans, there is relatively limited information from animal studies. Pharmacokinetic studies of chloroquine in both animal models and in human subjects indicate that chloroquine has quite a long half-life (Mzayek et al., 2007; Lim et al., 2009; Karunajeewa et al., 2010; Moore et al., 2011) , indicating that drug clearance is unlikely to be a limiting factor in the potential capacity of chloroquine to suppress of autophagy.
However, the maximal concentrations of chloroquine achieved in the plasma fall only within the range of 1.5 and 3µM, even with daily administration of the drug, concentrations which are unlikely to be sufficient to effectively interfere with autophagy (based on the concentrations required for autophagy inhibition in cell culture). It should however be noted that chloroquine accumulates in the lysosomes within cells and plasma levels may therefore not accurately reflect the levels in tumor tissues, especially when chloroquine treatment occurs over a long period of time. Overall, the variable effectiveness of chloroquine in enhancing sensitivity to chemotherapy and radiation in animal studies may relate to differences in the capacity of tumor models to accumulate chloroquine as well as differential sensitivity of tumors to autophagy inhibition by chloroquine. Consequently, a more potent autophagy inhibitor that might be developed for clinical use could actually prove to be quite effective as an adjunctive therapy.
Finally, although chloroquine is perhaps the most widely used drug to inhibit autophagy in vitro, and its effects on cell death have been directly attributed to its inhibition of autophagy, the mechanism by which chloroquine induces cell death could involve other functions independent of its ability to block autophagy that are less well characterized. Among these, chloroquine can decrease sequestration of anti-cancer drugs such as doxorubicin and mitoxantrone in endosomes by raising endosomal pH, thereby increasing their availability and cytotoxicity (Solomon and preventing long term observational studies. In one similar study where the effect of chloroquine on radiation sensitivity was investigated in 4T1 cells (Jiang et al, 2010) , and where the animals were injected with twice the number of cells as in the current work, no impact of chloroquine treatment on radiation-inhibited tumor growth was detected until 37 days post-challenge. This may relate to the development of hypoxia, as proposed Rouschop et al. (2012) and that is further discussed below.
Studies of radiation sensitization by chloroquine that were performed in HCT-116 colon carcinoma and U373 glioblastoma cells (Rouschop et al, 2010) provide unequivocal evidence of tumor growth delay by the combination treatment, which is ascribed to a reduction of hypoxiainduced autophagy by chloroquine. Of note, the growth curves for radiation alone and for chloroquine + radiation did not begin to diverge until after 14 days, which presumably reflects the time required for the tumors to become hypoxic. This may explain, in part, the lack of sensitization to radiation in our own animal studies, where the experiments were necessarily terminated after 15-18 days due to animal health and safety concerns.
It is further of interest that in the studiest by Rouschop et al. (2010) sensitization to radiation did not occur in cell culture under either normoxic or hypoxic conditions, which is consistent with our findings in 4T1 cells. We also observed that neither chloroquine nor 3-MA conferred radiation sensitization in Hs578t breast tumor cells (unpublished observations). Taken together, these studies argue that radiation does not uniformly promote a cytoprotective form of autophagy that can be exploited for the purpose of tumor cell sensitization. This inconsistency in the effectiveness of chloroquine clearly also appears to be the case for chemotherapeutic drugs, where the effectiveness or lack thereof of this approach is likely to be drug and tumor specific.
Conclusions It is worth considering that studies in xenograft models alone may be insufficient for accurately determining the capacity of autophagy inhibition to sensitize tumors to chemotherapy or radiation as a recent elegant study has shown that therapeutic success may be highly dependent on the immune system. In this work, anthracyclines and oxaliplatin did not alter the proliferation of tumors growing in athymic mice but only in immune-competent animals; furthermore, autophagy was determined to be essential for the release of immunogenic ATP from dying cells (Michaud et al., 2011; Martins et al., 2012) ; these findings indicate that syngeneic models of cancer and xenografts are likely to demonstrate uniquely different responses to therapeutic approaches involving autophagy induction or inhibition.
In additional preliminary studies in both non-small cell lung cancer cell lines and head and neck cancer cell lines, we have observed that autophagy inhibition by chloroquine does not consistently enhance radiation sensitivity (unpublished observations). Taken together with the studies in animal models discussed in this review, it can be predicted that autophagy inhibition is unlikely to be uniformly effective in increasing radiation or chemotherapeutic sensitivity across the tumor spectrum. However, this is not unusual or unexpected given that the sensitivities of malignancies of different origins to chemotherapeutic approaches can differ by orders of magnitude.
It is possible, but as yet untested, that the strength of autophagy induction in each system might determine its susceptibility to autophagy inhibition and sensitization. However, as autophagy is a dynamic process and as autophagy related proteins are expressed and regulated differently among tissues (Klionsky et al., 2012) , it is currently quite difficult to quantify and compare the degree of induction caused by different drugs, especially in vivo.
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Accepting the premise that autophagy inhibition can potentially serve to promote chemosensitization and radiosensitization, it follows that it will be critical to identify biomarkers that will distinguish between malignancies that are likely to benefit from autophagy inhibition as a strategy for chemosensitization or radiation sensitization and those tumors which are unlikely to benefit from this therapeutic approach. Furthermore, it will be necessary to establish that the drug(s) used to modulate autophagy are capable of achieving and maintaining concentrations in the tumor cells that will suppress autophagy, possibly throughout the course of treatment.
However, in considering the variability and uncertainty in the current literature relating to autophagy inhibition as a therapeutic strategy, caution appears to be warranted in extrapolating to the clinic from the limited preclinical data in animal models of cancer that have combined chloroquine with chemotherapy or radiotherapy. jpet.aspetjournals.org
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